Compare · DYNT vs WST
DYNT vs WST
Side-by-side comparison of Dynatronics Corporation (DYNT) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DYNT and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.34B, about 1634.3x DYNT ($14.3M).
- Over the past year, DYNT is up 0.0% and WST is up 46.0% - WST leads by 46.0 points.
- WST has hit the wire 5 times in the past 4 weeks while DYNT has been quiet.
- WST has more recent analyst coverage (17 ratings vs 0 for DYNT).
- Company
- Dynatronics Corporation
- West Pharmaceutical Services Inc.
- Price
- $0.24+12.55%
- $328.50-0.60%
- Market cap
- $14.3M
- $23.34B
- 1M return
- +0.00%
- +8.67%
- 1Y return
- +0.00%
- +46.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 17
Dynatronics Corporation
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. It offers orthopedic soft bracing products, which include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. The company also provides power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, recumbent bikes, and other related equipment. In addition, it offers therapeutic modality devices, such as electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. Further, the company provides clinical supplies, including exercise bands and tubing, topical analgesics, lotions and gels, orthopedic bracing, paper products, athletic tapes, and other related supplies. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, and athletic trainers, sports medicine practitioners, hospitals, clinics, and consumers, as well as online. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Eagan, Minnesota.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest DYNT
- Dynatronics Corporation filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update
- Dynatronics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Dynatronics Corporation
- SEC Form NT 10-Q filed by Dynatronics Corporation
- Large owner Essig Stuart acquired 16,095 shares, increasing direct ownership by 0.30% to 4,533,824 units (SEC Form 4)
- Large owner Provco Ventures 1 Lp acquired 8,043 shares, increasing direct ownership by 0.29% to 2,739,998 units (SEC Form 4)
- Director Enright Erin S. acquired 16,095 shares (SEC Form 4)
- President & CEO, CFO Baker Brian D. acquired 1,130 shares, increasing direct ownership by 0.30% to 382,675 units (SEC Form 4)
- SEC Form DEFA14A filed by Dynatronics Corporation
- SEC Form DEF 14A filed by Dynatronics Corporation
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)